Skin Type and Conjunctival Melanoma: How Phototype Shapes Clinical Features and Prognosis
When discussing melanoma risks, most public awareness centers on sun-exposed areas of the skin. However, melanomas can also arise on the ocular surface, specifically the conjunctiva. To understand whether a patient's baseline phototype influences how these rare tumors develop and behave, researchers conducted a large retrospective evaluation. This Q&A explainer breaks down the findings from the 2020 investigation into ocular surface melanoma across different skin phototypes.
What Is Conjunctival Melanoma and How Was It Studied?
Conjunctival melanoma is an uncommon malignancy that develops on the mucous membrane covering the front of the eye and lining the inside of the eyelids. Because skin pigmentation categories are widely used to assess cutaneous cancer risks, researchers set out to determine whether baseline skin traits correspond to variations in ocular surface disease.
The primary evidence comes from a 2020 paper titled Conjunctival Melanoma: Features and Outcomes Based on the Fitzpatrick Skin Type in 540 Patients at a Single Ocular Oncology Center, published in Ophthalmic Plastic and Reconstructive Surgery. In this single-center retrospective case series, investigators reviewed medical records for 540 patients diagnosed with conjunctival melanoma to evaluate clinical presentations and long-term therapeutic outcomes sorted by baseline Fitzpatrick skin type (FST).
How Were Fitzpatrick Skin Types Distributed Among Patients?
The Fitzpatrick skin types classify complexion based on natural coloring and reactions to daylight exposure, scaling from Type I (lightest) to Type VI (darkest). Across the 540 patients evaluated in the study, the vast majority presented with very fair complexions:
- Type I: 126 patients (23%)
- Type II: 337 patients (62%)
- Type III: 56 patients (10%)
- Type IV: 8 patients (2%)
- Type V: 12 patients (2%)
- Type VI: 1 patient (<1%)
Altogether, Types I and II accounted for 85% of all cases in the series, showing that individuals with fair skin represented the overwhelming majority of patients treated for this malignancy at the ocular center.
Did Presentation and Tumor Thickness Vary by Skin Type?
When the investigators analyzed the clinical presentations by grouping patients into Type I, Type II, and a combined cohort of Types III, IV, V, and VI, significant variations emerged across several key diagnostic metrics:
- Mean Patient Age: Patients with Type I presented at an older mean age of 63.9 years, compared to 60.7 years for Type II and 51.1 years for Types III through VI (p < 0.001).
- Sex Distribution: Women made up 68% of the Type I group, compared to 44% in Type II and 42% in Types III through VI (p < 0.001).
- Complexion Associated Melanosis: This finding occurred in only 1% of Type I patients and 2% of Type II patients, but rose to 13% among patients in the combined Types III through VI group (p < 0.001).
- Tumor Thickness: Mean tumor thickness was smallest in Type I at 2.1 mm, measured 2.8 mm in Type II, and reached 3.6 mm in Types III through VI (p = 0.01).
- Eyelid Involvement: Eyelid involvement occurred in 13% of Type I cases, 13% of Type II cases, and 28% of cases within Types III through VI (p = 0.02).
These data indicate that while individuals with darker skin phototypes developed conjunctival melanoma far less frequently in this cohort, those who did presented at younger average ages with thicker primary tumors and higher rates of eyelid involvement.
Does Baseline Skin Type Influence Long-Term Survival or Vision Loss?
Despite the differences seen at baseline examination, the study found that skin type did not translate into different long-term survival or structural outcomes. Using Kaplan-Meier estimates to evaluate 5-year risks, the authors found no statistically significant difference between Fitzpatrick categories for several critical milestones:
- Visual acuity loss of 3 or more lines
- Local tumor recurrence
- Exenteration (surgical removal of the eye and surrounding orbital tissues)
- Systemic metastasis
- Patient death
Consequently, while baseline features like primary tumor thickness and age varied at presentation, a patient's Fitzpatrick phototype did not dictate their five-year odds of recurrence, vision loss, or mortality once managed at the specialized oncology center.
What Are the Study's Design Limits and Clinical Takeaways?
While the data set of 540 patients is substantial for an uncommon malignancy, several design constraints must be recognized. As stated in the published report, this was a retrospective case series conducted at a single tertiary ocular oncology center. Retrospective reviews rely on historical medical charts, which can introduce referral and observational selection factors.
Furthermore, because conjunctival melanoma was predominantly observed in individuals with Type I and Type II complexions, sample sizes for Types IV, V, and VI were very small (8, 12, and 1 patient, respectively). These limited counts restrict definitive statistical comparisons for individual darker phototypes, requiring them to be analyzed collectively.
For individuals concerned about ocular health, changes on the eye surface warrant professional attention regardless of one's complexion. Protecting ocular structures from broad light exposure through physical measures like UV-rated eyewear remains an established general safety recommendation covered in our guide on sunglasses and UV protection. Anyone noting new, irregular, or darkening pigmentation on the conjunctiva or eyelids should promptly consult an ophthalmologist or dermatologist for an in-person clinical evaluation.
Sources
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.